Tag: msi-h and dmmr market growth

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

MSI-H And dMMR Market Value Growth And Long-Term Outlook

The market size for msi-h and dmmr has demonstrated exponential growth in recent years. It is anticipated to increase from $7.57 billion in 2025 to $9.32 billion in 2026, at a compound annual growth rate (CAGR) of 23.1%. The growth observed in the historical period can be attributed to factors such as the discovery of msi-h and dmmr biomarkers, the initial success of immune checkpoint inhibitors, a rising incidence of colorectal and endometrial cancer, the expansion of molecular diagnostics, and regulatory approvals for biomarker-based therapies.

The market for msi-h and dmmr is projected to experience rapid expansion in the coming years. Its valuation is set to reach $21.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.7%. This anticipated growth during the projected timeframe stems from factors such as increased uptake of precision oncology, a rise in genomic testing applications in cancer treatment, broader approval for immunotherapy uses, higher investment in biomarker studies, and accumulating clinical data favoring tumor-agnostic strategies. Key trends expected over the forecast period encompass a greater acceptance of immunotherapy for msi-h and dmmr tumors, an expanding application of companion diagnostics for classifying patients, an escalating emphasis on cancer treatments that are tumor-agnostic, the proliferation of combination immunotherapy protocols, and heightened understanding of oncology approaches guided by biomarkers.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=28529543&type=smp&name=MSI-H%20And%20dMMR%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

MSI-H And dMMR Market Growth Backed By Core Demand Fundamentals

The increasing occurrence of cancer is projected to drive the expansion of the MSI-H and dMMR market in the future. Cancer is defined as a collection of illnesses marked by the unregulated multiplication and dissemination of atypical cells throughout the body. This upward trend in cancer cases is largely attributed to demographic aging, considering that the likelihood of developing cancer rises considerably with advancing age due to the accumulated impact of genetic alterations and extended exposure to various risk factors over a lifetime. In oncology, MSI-H and dMMR markers serve to pinpoint tumors exhibiting elevated mutation rates, a consequence of imperfections in DNA repair processes. These particular biomarkers are instrumental in informing immunotherapy choices, given that these types of tumors show a greater propensity to react positively to immune checkpoint inhibitors; furthermore, they offer valuable information regarding patient prognosis and the possibility of underlying genetic syndromes. For example, data released in January 2024 by the American Cancer Society, a non-profit organization based in the US, indicated that in 2023, approximately 1,958,310 new cancer diagnoses and 609,820 fatalities linked to cancer were anticipated in the United States. These figures are forecast to increase in 2024, with around 2,001,140 new cancer cases and 611,720 deaths expected, thereby underscoring an ongoing escalation in both the occurrence and fatality rates of cancer. Consequently, the expanding incidence of cancer is a key factor fueling the expansion of the MSI-H and dMMR market.

MSI-H And dMMR Market Segment Landscape: Which Areas Lead Development?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

MSI-H And dMMR Market Growth Trends Reshaping The Competitive Landscape

Leading companies in the MSI-H and dMMR market are concentrating on developing innovative treatments, such as combination therapy, to enhance treatment effectiveness and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves utilizing two or more distinct treatment modalities, frequently immunotherapy agents like checkpoint inhibitors, or integrating immunotherapy with chemotherapy, targeted therapy, or radiation. This approach aims to boost treatment response, overcome resistance mechanisms, and improve survival rates in patients with tumors exhibiting high microsatellite instability or deficient mismatch repair. For example, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical entity, obtained United States Food and Drug Administration (FDA) approval for the combined use of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) characteristics, thereby advancing therapeutic options for this challenging cancer subtype. This approval signifies a major breakthrough in managing MSI-H and dMMR cancers, as it introduces an effective new therapeutic alternative that targets multiple pathways to enhance patient survival and response rates, addressing crucial unmet medical needs in this patient population.

MSI-H And dMMR Market Industry Leaders And Competitive Landscape

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

View The Full MSI-H And dMMR Market Report:

https://thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

MSI-H And dMMR Market Geographic Spread And Regional Opportunities

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

MSI-H And dMMR Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for MSI-H and dMMR has experienced exponential expansion in recent years. Projected to increase from $7.57 billion in 2025 to $9.32 billion in 2026, this represents a compound annual growth rate (CAGR) of 23.1%. Several factors have driven growth during the historical period, including the identification of MSI-H and dMMR biomarkers, the initial effectiveness of immune checkpoint inhibitors, a growing incidence of colorectal and endometrial cancers, the broadening use of molecular diagnostic tools, and the regulatory endorsement of therapies targeting these biomarkers.

The msi-h and dmmr market size is projected to undergo exponential expansion over the coming years, reaching $21.13 billion by 2030 with a compound annual growth rate (CAGR) of 22.7%. This growth during the forecast period is driven by factors such as the rising adoption of precision oncology, the increased application of genomic testing in cancer care, the broadening of immunotherapy indications, heightened investment in biomarker research, and accumulating clinical evidence that supports tumor-agnostic strategies. Key trends shaping this period include the growing adoption of immunotherapy for msi-h and dmmr tumors, the expanding use of companion diagnostics to stratify patients, an increasing emphasis on tumor-agnostic cancer therapies, the development of combination immunotherapy protocols, and heightened awareness surrounding biomarker-driven oncology.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

MSI-H And dMMR Market Demand Drivers: What Is Fueling Industry Growth?

The growing incidence of cancer is expected to drive expansion in the MSI-H and dMMR market in the coming years. Cancer encompasses a range of diseases marked by the unregulated proliferation and dissemination of abnormal cells throughout the body. This upward trend in cancer cases is largely attributed to aging populations, given that the likelihood of developing cancer escalates significantly with age, stemming from the buildup of genetic mutations and extended exposure to risk factors over time. MSI-H and dMMR are utilized in oncology to detect tumors exhibiting high mutation rates due to impairments in DNA repair mechanisms. These biomarkers assist in steering immunotherapy strategies, since such tumors tend to respond favorably to immune checkpoint inhibitors, while also offering clues about prognosis and potential hereditary conditions. For example, in January 2024, the American Cancer Society—a US nonprofit organization—reported that approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths were forecast for 2023 in the United States. These figures are expected to grow in 2024, with around 2,001,140 new cases and 611,720 deaths predicted, underscoring a sustained rise in both cancer occurrence and mortality. As a result, the escalating prevalence of cancer is fueling momentum in the MSI-H and dMMR market.

MSI-H And dMMR Market Segment Outlook: Which Categories Are Expanding The Fastest?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

MSI-H And dMMR Market Innovation Trends: Which Developments Are Transforming The Industry?

Key players in the MSI-H and dMMR market are concentrating on the creation of novel therapies, including combination strategies, to boost treatment effectiveness and improve outcomes for patients. For MSI-H and dMMR cancers, combination therapy integrates two or more treatment methods, frequently immune checkpoint inhibitors or a mix of immunotherapy with chemotherapy, targeted therapies, or radiation. This strategy is intended to heighten treatment responses, counteract resistance, and extend survival for individuals with tumors characterized by high microsatellite instability or deficient mismatch repair. A notable example occurred in April 2025 when Bristol-Myers Squibb Company, a pharmaceutical firm based in the United States, secured approval from the United States Food and Drug Administration (FDA) for the combined use of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line intervention for metastatic colorectal cancer (mCRC) displaying MSI-H or dMMR properties, thereby broadening therapeutic possibilities for this difficult cancer type. This authorization represents a major advancement in managing MSI-H and dMMR cancers by introducing an effective new option that engages multiple pathways to elevate patient survival and response rates, thereby fulfilling the unmet needs of this patient segment.

MSI-H And dMMR Market Key Companies And Competitive Benchmarking

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Access The Complete MSI-H And dMMR Market Report:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

MSI-H And dMMR Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The MSI-H And dMMR Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The msi-h and dmmr market has experienced substantial growth in recent years. It is anticipated to expand from $7.57 billion in 2025 to $9.32 billion in 2026, showing a compound annual growth rate (CAGR) of 23.1%. This historical growth can be attributed to the discovery of msi-h and dmmr biomarkers, the early success of immune checkpoint inhibitors, a rise in colorectal and endometrial cancer incidence, the expansion of molecular diagnostics, and regulatory approvals for biomarker-based therapies.

The msi-h and dmmr market size is expected to undergo substantial growth over the next few years. It is forecast to expand to $21.13 billion by 2030, achieving a compound annual growth rate (CAGR) of 22.7%. This growth trajectory during the forecast period is primarily driven by factors such as the increasing adoption of precision oncology, the expanded use of genomic testing in cancer care, the broadening of immunotherapy indications, rising investment in biomarker research, and the accumulation of clinical evidence supporting tumor-agnostic approaches. Prominent trends anticipated in the forecast period include the increasing uptake of immunotherapy for msi-h and dmmr tumors, the growing application of companion diagnostics for patient stratification, a heightened focus on tumor-agnostic cancer treatments, the expansion of combination immunotherapy regimens, and increased awareness of biomarker-driven oncology.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

What Influential Factors Are Boosting The MSI-H And dMMR Market Demand?

The increasing incidence of cancer is anticipated to drive expansion in the MSI-H and dMMR market in the future. Cancer is defined as a collection of illnesses marked by the uncontrolled multiplication and dispersion of atypical cells throughout the body. The growing occurrence of cancer largely stems from an aging global population, given that the likelihood of developing cancer rises considerably with advancing age due to the accumulated impact of genetic alterations and extended exposure to various risk factors over many years. In oncology, MSI-H and dMMR serve to pinpoint tumors exhibiting elevated mutation rates resulting from deficiencies in DNA repair pathways. These biological markers assist in directing immunotherapy choices, since these particular tumors show a greater propensity to react positively to immune checkpoint inhibitors; moreover, they offer valuable information regarding patient prognosis and the presence of possible genetic syndromes. As an illustration, in January 2024, data from the American Cancer Society, a US-based non-profit organization, indicated that in 2023, approximately 1,958,310 new cancer diagnoses and 609,820 cancer fatalities were projected for the United States. These figures are forecasted to climb in 2024, with around 2,001,140 new cancer diagnoses and 611,720 deaths expected, underscoring an ongoing upward trend in cancer occurrence and fatalities. Consequently, the increasing prevalence of cancer is a key factor propelling the expansion of the MSI-H and dMMR market.

Which Segment Groups Define The MSI-H And dMMR Market Landscape?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Trends Are Influencing The MSI-H And dMMR Market?

Leading companies within the MSI-H and dMMR market are prioritizing the development of innovative therapies, particularly combination approaches, to elevate treatment effectiveness and enhance patient prognosis. This type of therapy for MSI-H and dMMR cancers integrates two or more distinct treatment methods, frequently utilizing immunotherapy agents such as checkpoint inhibitors, or combining immunotherapy with other modalities like chemotherapy, targeted therapy, or radiation. The objective of this strategy is to boost treatment responsiveness, circumvent resistance mechanisms, and extend survival rates in patients whose tumors display high microsatellite instability or deficient mismatch repair. As a notable instance, in April 2025, the US-based pharmaceutical company Bristol-Myers Squibb Company secured approval from the United States Food and Drug Administration (FDA) for the combined use of nivolumab (Opdivo) and ipilimumab (Yervoy). This combination was approved as a first-line treatment for metastatic colorectal cancer (mCRC) characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features, thereby advancing therapeutic possibilities for this challenging subtype of cancer. This FDA clearance signifies a crucial advancement in the treatment landscape for MSI-H and dMMR cancers, introducing a novel and potent therapeutic alternative that targets multiple biological pathways to improve patient survival and response rates, thereby addressing previously unmet medical requirements in this patient population.

Who Are The Firms Contributing To The MSI-H And dMMR Market Ecosystem?

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Access The Complete MSI-H And dMMR Market Report:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Region Contributes The Most To The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access MSI-H And dMMR Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2026, By The Business Research Company

Automotive Human Machine Interface Hmi Market Report 2026

https://www.thebusinessresearchcompany.com/report/automotive-human-machine-interface-hmi-global-market-report

Electronic Data Interchange Edi Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/electronic-data-interchange-edi-software-global-market-report

Digital Aerospace Mro Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-aerospace-mro-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The MSI-H And dMMR Market Projected To Reach By 2030?

The market size for msi-h and dmmr has seen substantial growth in recent years. It is projected to expand from $7.57 billion in 2025 to $9.32 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 23.1%. The increase observed in the past can be credited to the discovery of msi-h and dmmr biomarkers, the initial success of immune checkpoint inhibitors, the escalating incidence of colorectal and endometrial cancer, the broadening scope of molecular diagnostics, and regulatory approvals for therapies based on biomarkers.

The msi-h and dmmr market size is anticipated to experience substantial growth in the coming years. It is projected to reach $21.13 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 22.7%. This expansion during the forecast period is fueled by factors such as the increasing adoption of precision oncology, the growing application of genomic testing in cancer care, the broadening of immunotherapy indications, rising investments in biomarker research, and the accumulation of clinical evidence supporting tumor-agnostic approaches. Prominent trends within this period are expected to include the heightened use of immunotherapy for msi-h and dmmr tumors, increased reliance on companion diagnostics for patient stratification, an elevated focus on tumor-agnostic cancer treatments, the proliferation of combination immunotherapy regimens, and enhanced awareness of biomarker-driven oncology.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which Primary Drivers Are Impacting The MSI-H And dMMR Market Growth?

The MSI-H and dMMR market is expected to experience growth due to the increasing prevalence of cancer. Cancer is a group of diseases defined by the uncontrolled multiplication and spread of abnormal cells within the body. This escalation in cancer cases is primarily linked to aging populations, as the risk of developing cancer significantly rises with age, owing to the cumulative impact of genetic mutations and prolonged exposure to various risk factors over time. In cancer treatment, MSI-H and dMMR are utilized to identify tumors that exhibit high mutation rates due to deficiencies in DNA repair mechanisms. These biomarkers are crucial for guiding immunotherapy decisions, given that such tumors often respond better to immune checkpoint inhibitors, and they also provide insights into patient prognosis and potential genetic syndromes. For example, in January 2024, the American Cancer Society, a US-based non-profit organization, indicated that in 2023, the United States was estimated to have 1,958,310 new cancer cases and 609,820 cancer-related deaths. These figures are projected to climb in 2024, with approximately 2,001,140 new cancer cases and 611,720 deaths anticipated, thereby highlighting a continuous rise in cancer incidence and mortality. Hence, the growing prevalence of cancer is a key driver for the expansion of the MSI-H and dMMR market.

What Segment Categories Shape The MSI-H And dMMR Market Segment Landscape?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

Which Trends Are Influencing Demand In The MSI-H And dMMR Market?

Leading companies in the MSI-H and dMMR market are concentrating on developing innovative treatments, such as combination therapy, to boost treatment effectiveness and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves utilizing two or more treatment methods, frequently immunotherapy agents like checkpoint inhibitors, or integrating immunotherapy with chemotherapy, targeted therapy, or radiation. This strategy aims to enhance treatment response, overcome resistance, and extend survival for patients with tumors that exhibit high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, secured United States Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line therapy for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features, thereby advancing treatment options for this challenging cancer subtype. This approval signifies a major milestone in the management of MSI-H and dMMR cancers, as it introduces an effective new therapeutic choice that targets multiple pathways to enhance patient survival and response rates, addressing unmet medical needs in this patient population.

Who Are The Companies Operating Across The MSI-H And dMMR Market Value Chain?

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Get The Full MSI-H And dMMR Market Report:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Region Accounts For The Largest Portion Of The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized MSI-H And dMMR Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2026, By The Business Research Company

Automotive Human Machine Interface Hmi Market Report 2026

https://www.thebusinessresearchcompany.com/report/automotive-human-machine-interface-hmi-global-market-report

Electronic Data Interchange Edi Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/electronic-data-interchange-edi-software-global-market-report

Digital Aerospace Mro Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-aerospace-mro-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The MSI-H And dMMR Market During The Forecast Period 2026–2030?

The msi-h and dmmr market has experienced substantial growth in recent years. Its value is anticipated to rise from $7.57 billion in 2025 to $9.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.1%. This historical expansion can be attributed to several factors, including the identification of msi-h and dmmr biomarkers, the early success observed with immune checkpoint inhibitors, the increasing incidence of colorectal and endometrial cancer, the wider availability of molecular diagnostics, and the regulatory approvals granted for therapies based on biomarkers.

The market size for msi-h and dmmr is projected to experience substantial expansion over the coming years, anticipated to reach $21.13 billion by 2030 with a compound annual growth rate (CAGR) of 22.7%. This growth during the forecast period is attributable to the increasing adoption of precision oncology, the wider application of genomic testing in cancer care, the broadening of immunotherapy indications, a surge in investment in biomarker research, and the accumulation of clinical evidence supporting tumor-agnostic approaches. Key trends anticipated in the same period involve the rising uptake of immunotherapy for msi-h and dmmr tumors, the expanding role of companion diagnostics in patient stratification, a heightened emphasis on tumor-agnostic cancer therapies, the proliferation of combination immunotherapy regimens, and enhanced recognition of biomarker-driven oncology.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which Major Factors Are Driving The Expansion Of The MSI-H And dMMR Market?

The increasing occurrence of cancer is projected to drive the expansion of the MSI-H and dMMR market in the future. Cancer encompasses a collection of illnesses defined by the uncontrolled proliferation and dissemination of atypical cells throughout the body. The growing incidence of cancer can largely be attributed to aging demographics, as the probability of developing cancer rises considerably with age due to the combined effect of genetic alterations and extended exposure to risk factors over time. Within cancer treatment, MSI-H and dMMR are employed to pinpoint tumors exhibiting elevated mutation rates stemming from deficiencies in DNA repair mechanisms. These specific biomarkers are instrumental in directing immunotherapy choices, given that such tumors often show a greater likelihood of responding to immune checkpoint inhibitors, and they also offer valuable information regarding prognosis and possible genetic syndromes. For example, in January 2024, data from the American Cancer Society, a US-based non-profit organization, indicated that in 2023, an estimated 1,958,310 new cancer cases and 609,820 cancer-related deaths were expected in the United States. These figures are forecast to increase in 2024, with approximately 2,001,140 new cancer cases and 611,720 deaths anticipated, underscoring an ongoing rise in both cancer incidence and mortality. Consequently, the rising prevalence of cancer is a key factor stimulating the growth of the MSI-H and dMMR market.

What Market Segments Are Evaluated Within The MSI-H And dMMR Market?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Industry Trends Are Redefining The MSI-H And dMMR Market?

Leading companies active in the MSI-H and dMMR market are concentrating on creating advanced treatments, such as combination therapy, to boost treatment effectiveness and better patient results. This strategy for MSI-H and dMMR cancers entails employing two or more treatment methods, frequently including immunotherapy agents like checkpoint inhibitors, or combining immunotherapy with chemotherapy, targeted therapy, or radiation. The goal is to improve treatment response, circumvent resistance, and prolong survival in individuals whose tumors display high microsatellite instability or deficient mismatch repair. As an illustration, in April 2025, the US-based pharmaceutical company, Bristol-Myers Squibb Company, secured United States Food and Drug Administration (FDA) approval for its nivolumab (Opdivo) and ipilimumab (Yervoy) combination as a primary treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) characteristics, thereby expanding therapeutic choices for this complex cancer subtype. This approval represents a pivotal achievement in the management of MSI-H and dMMR cancers, providing a novel, potent therapeutic alternative that addresses various pathways to elevate patient survival and response rates, thus meeting significant unmet medical requirements within this patient demographic.

Who Are The Top Market Participants Influencing The MSI-H And dMMR Market?

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Read the full msi-h and dmmr market report here:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Region Currently Holds The Largest Share Of The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored MSI-H And dMMR Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2026, By The Business Research Company

Automotive Human Machine Interface Hmi Market Report 2026

https://www.thebusinessresearchcompany.com/report/automotive-human-machine-interface-hmi-global-market-report

Electronic Data Interchange Edi Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/electronic-data-interchange-edi-software-global-market-report

Digital Aerospace Mro Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-aerospace-mro-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the msi-h and dmmr market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the MSI-H And dMMR Market in 2026, and what figure is it projected to hit by 2030?

The msi-h and dmmr market has witnessed substantial expansion in recent years. It is projected to grow from $7.57 billion in 2025 to $9.32 billion in 2026, registering a compound annual growth rate (CAGR) of 23.1%. This historical growth can be ascribed to factors such as the discovery of msi-h and dmmr biomarkers, the initial success of immune checkpoint inhibitors, a rising incidence of colorectal and endometrial cancer, the expansion of molecular diagnostics, and regulatory approvals for biomarker-based therapies.

The msi-h and dmmr market is projected for significant expansion in the coming years, expected to reach $21.13 billion by 2030, propelled by a compound annual growth rate (CAGR) of 22.7%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing adoption of precision oncology, wider utilization of genomic testing in cancer treatment, the broadening of immunotherapy applications, heightened investment in biomarker research, and the accumulation of clinical evidence favoring tumor-agnostic strategies. Key trends anticipated within this period encompass the growing embrace of immunotherapy for msi-h and dmmr tumors, greater reliance on companion diagnostics for patient classification, an elevated focus on tumor-agnostic cancer therapies, the proliferation of combination immunotherapy regimens, and enhanced recognition of biomarker-driven oncology.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which Drivers Are Affecting Market Participation In The MSI-H And dMMR Market?

The increasing occurrence of cancer is anticipated to drive expansion in the MSI-H and dMMR market moving ahead. Cancer is defined as a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells throughout the body. This increase in cancer prevalence mainly stems from aging demographics, given that the likelihood of developing cancer substantially rises with advancing age, owing to the cumulative impact of genetic alterations and extended exposure to various risk factors over a period. Within cancer contexts, MSI-H and dMMR markers are utilized to pinpoint tumors exhibiting elevated mutation rates, which result from deficiencies in DNA repair systems. These biological markers assist in directing immunotherapy choices, since these particular tumors show a greater propensity to react to immune checkpoint inhibitors, and concurrently, they offer valuable information regarding patient prognosis and possible genetic syndromes. For example, as reported in January 2024 by the American Cancer Society, a US-based non-profit organization, projections for 2023 indicated that the United States would see an estimated 1,958,310 new cancer diagnoses and 609,820 fatalities linked to cancer. These figures are forecasted to climb in 2024, with an approximate 2,001,140 new cancer cases and 611,720 deaths predicted, underscoring an ongoing upward trend in both cancer occurrence and mortality rates. Consequently, the growing incidence of cancer is propelling the expansion of the MSI-H and dMMR market.

What Segment Categories Are Covered In The MSI-H And dMMR Market?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Trends Are Driving The Growth Trajectory Of The MSI-H And dMMR Market?

Leading companies operating in the MSI-H and dMMR market are concentrating on developing innovative treatments, such as combination therapy, to enhance treatment efficacy and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves utilizing two or more treatment modalities, commonly including immunotherapy agents like checkpoint inhibitors or combining immunotherapy with chemotherapy, targeted therapy, or radiation. This approach aims to boost treatment response, overcome resistance, and improve survival outcomes in patients with tumors exhibiting high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received United States Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features, further advancing therapeutic options for this challenging cancer subtype. This approval signifies a major milestone in the treatment of MSI-H and dMMR cancers, as it introduces a new, effective therapeutic option that targets multiple pathways to improve patient survival and response rates, thereby addressing the unmet medical needs in this patient population.

Which Major Industry Participants Are Leading The MSI-H And dMMR Market Growth?

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized MSI-H And dMMR Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2026, By The Business Research Company

Automotive Human Machine Interface Hmi Market Report 2026

https://www.thebusinessresearchcompany.com/report/automotive-human-machine-interface-hmi-global-market-report

Electronic Data Interchange Edi Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/electronic-data-interchange-edi-software-global-market-report

Digital Aerospace Mro Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-aerospace-mro-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the msi-h and dmmr market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The MSI-H And dMMR Market Now And By 2029?

The market for MSI-H and dMMR has seen rapid expansion in recent years. It is projected to grow from $6.15 billion in 2024 to $7.57 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 23.0%. This historic growth can be attributed to several factors including a rising incidence of colorectal and endometrial cancers, expanded genetic screening programs, increasing clinical adoption of MSI testing, greater awareness of hereditary cancer syndromes, and a rise in the use of liquid biopsy.

The market size for MSI-H and dMMR is predicted to undergo substantial growth in the forthcoming years. It is forecast to expand to $17.26 billion in 2029, achieving a compound annual growth rate (CAGR) of 22.9%. The increase during this projected period can be attributed to several factors, including a heightened demand for personalized cancer therapies, the expanding applications of next-generation sequencing, increased healthcare expenditure in oncology, the proliferation of clinical trials for immune checkpoint inhibitors, and robust regulatory support for companion diagnostics. Significant trends anticipated over the forecast period involve the integration of artificial intelligence into diagnostic workflows, strategic partnerships between pharmaceutical and diagnostic companies, the evolution of multiplex biomarker panels, advancements in immunotherapy, and a notable shift towards pan-cancer biomarker testing.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which Long-Term Drivers Are Expected To Sustain The MSI-H And dMMR Market?

The increasing occurrence of cancer is projected to drive expansion in the MSI-H and dMMR market moving forward. Cancer constitutes a set of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body. The growing incidence of cancer is largely attributed to aging demographics, given that the likelihood of developing cancer markedly rises with advancing age due to the combined impact of genetic alterations and extended exposure to risk factors over a period. In cancer treatment, MSI-H and dMMR serve to pinpoint tumors exhibiting elevated mutation rates stemming from deficiencies in DNA repair systems. These biological markers aid in directing immunotherapy choices, since these particular tumors show a greater propensity to react to immune checkpoint inhibitors, while also offering clarity on prognosis and potential inherited conditions. As an illustration, in January 2024, the American Cancer Society, a US-based non-profit organization, reported that for 2023, approximately 1,958,310 new cancer diagnoses and 609,820 cancer-related fatalities were anticipated in the United States. These figures are projected to climb in 2024, with around 2,001,140 new cancer cases and 611,720 deaths foreseen, underscoring an ongoing upward trend in cancer occurrence and fatality. Consequently, the increasing prevalence of cancer is stimulating the expansion of the MSI-H and dMMR market.

How Is The MSI-H And dMMR Market Classified By Different Segments?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Current And Upcoming Trends Are Shaping The MSI-H And dMMR Market?

Major companies active in the MSI-H and dMMR market are concentrating on developing innovative treatments, such as combination therapy, to boost treatment effectiveness and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves utilizing two or more treatment modalities, commonly immunotherapy agents like checkpoint inhibitors, or integrating immunotherapy with chemotherapy, targeted therapy, or radiation. This strategy aims to enhance treatment response, overcome resistance, and improve survival rates in patients whose tumors display high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical company, secured United States Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) characteristics, further progressing treatment alternatives for this difficult cancer subtype. This approval signifies a key milestone in the management of MSI-H and dMMR cancers, offering a new, effective therapeutic choice that targets multiple pathways to improve patient survival and response rates, thereby addressing the unmet medical needs in this patient population.

Who Are The Primary Market Leaders In The MSI-H And dMMR Market?

Major companies operating in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Regional Markets Are Emerging As Key Centers For The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2025, By The Business Research Company

Dna And Gene Chip Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-and-gene-chip-global-market-report

Dna Based Skin Care Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-based-skin-care-products-global-market-report

Dna Digital Data Storage Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-digital-data-storage-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The MSI-H And dMMR Market Size Likely To Evolve From 2025 Through 2034?

The MSI-H and dMMR market size has experienced significant expansion over recent years. It is anticipated to increase from $6.15 billion in 2024 to $7.57 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 23.0%. The growth observed in previous periods can be linked to a heightened incidence of colorectal and endometrial cancers, the broader implementation of genetic screening programs, an increasing clinical acceptance of MSI testing, growing awareness concerning hereditary cancer syndromes, and an uptick in the adoption of liquid biopsy.

The MSI-H and dMMR market size is projected to experience substantial growth in the upcoming years, with its value anticipated to reach “$17.26 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 22.9%. This expansion during the forecast period can be attributed to several factors, including an increasing demand for personalized cancer therapies, the broadening applications of next-generation sequencing, rising healthcare expenditure in oncology, a growing number of clinical trials for immune checkpoint inhibitors, and supportive regulatory frameworks for companion diagnostics. Major trends expected in the forecast period involve the integration of artificial intelligence into diagnostic workflows, collaborations between pharmaceutical and diagnostic companies, the development of multiplex biomarker panels, continuous advancements in immunotherapy, and a noticeable shift toward pan-cancer biomarker testing.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which Drivers Are Supporting Growth Of The MSI-H And dMMR Market?

The expanding incidence of cancer is anticipated to fuel the progress of the MSI-H and dMMR market moving forward. Cancer encompasses a range of illnesses marked by the unrestrained proliferation and dissemination of atypical cells within the body. The increasing occurrence of cancer is mainly attributed to aging demographics, as the probability of developing cancer rises considerably with age due to the accumulated impact of genetic alterations and prolonged exposure to risk factors. MSI-H and dMMR are employed in oncology to identify tumors exhibiting elevated mutation rates resulting from deficiencies in DNA repair pathways. These indicators aid in directing immunotherapy choices, given that such tumors often show a better response to immune checkpoint inhibitors, and they also offer insights into patient outlook and potential inherited conditions. For example, as reported by the American Cancer Society, a US-based non-profit organization, in January 2024, the United States recorded an estimated 1,958,310 new cancer cases and 609,820 cancer-related deaths in 2023. These figures are projected to climb in 2024, with around 2,001,140 new cancer cases and 611,720 deaths expected, underscoring a continuous upward trend in cancer incidence and mortality. Consequently, the increasing prevalence of cancer is propelling the expansion of the MSI-H and dMMR market.

What Are The Major Segments Identified In The MSI-H And dMMR Market?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Are The Major Trends Driving The Growth Of The MSI-H And dMMR Market?

Major companies operating in the MSI-H and dMMR market are focusing on developing innovative treatments, such as combination therapy, to enhance treatment efficacy and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves utilizing two or more treatment modalities, frequently immunotherapy agents such as checkpoint inhibitors or combining immunotherapy with chemotherapy, targeted therapy, or radiation. This approach aims to improve treatment response, overcome resistance, and extend survival outcomes in patients with tumors exhibiting high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received United States Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features, further advancing treatment options for this challenging cancer subtype. This approval signifies a substantial milestone in the treatment of MSI-H and dMMR cancers, as it provides a new, effective therapeutic option that targets multiple pathways to improve patient survival and response rates, addressing the unmet medical needs in this patient population.

Which Major Firms Are Strengthening Their Position In The MSI-H And dMMR Industry?

Major companies operating in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The MSI-H And dMMR Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2025, By The Business Research Company

Dna And Gene Chip Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-and-gene-chip-global-market-report

Dna Based Skin Care Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-based-skin-care-products-global-market-report

Dna Digital Data Storage Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-digital-data-storage-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The MSI-H And dMMR Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, there has been exceptional growth in the market size of MSI-H and dMMR. This market, valued at $6.15 billion in 2024, is projected to rise to $7.57 billion in 2025, indicating a compound annual growth rate (CAGR) of 23.0%. The significant advancement during the historical timeframe is linked with the escalating rate of colorectal and endometrial cancers, expanded genetic testing, increasing utilisation of MSI tests in clinical settings, surge in awareness of inherited cancer syndromes, and an increased adoption of liquid biopsies.

There is a prediction for a significant surge in the market size of MSI-H and dMMR in the coming years. At a Compound Annual Growth Rate (CAGR) of 22.9%, it is projected to reach a figure of $17.26 billion by 2029. Various factors contribute to this anticipated expansion, including the rising need for customised cancer treatments, evolving uses of next-generation sequencing, increasing expenditure in cancer treatment healthcare, the boost in clinical trials regarding immune checkpoint inhibitors, and supportive regulatory policies for companion diagnostics. Throughout the forecasted period, some notable trends are the incorporation of artificial intelligence into diagnostic procedures, the collab between pharmaceutical and diagnostic companies, the invention of multiplex biomarker panels, advancements in immunotherapy, and the trend towards pan-cancer biomarker testing.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of MSI-H And dMMR Market?

The anticipated growth of the MSI-H and dMMR market is largely driven by the increasing incidence of cancer. This term refers to several diseases having a common trait of unchecked growth and spread of abnormal cells within the body. The key factor behind the increasing cancer prevalence is the aging of populations, as cancer development risk substantially rises with age due to the accumulation of genetic mutations and long-term exposure to various risk factors. To identify tumors with high mutation rates resulting from uncorrected DNA repair errors, MSI-H and dMMR are used in cancer diagnostics. These biomarkers are instrumental in influencing decisions around immunotherapy due to the fact that such tumors likely yield a better response to immune checkpoint inhibitors. They also give insight into prognosis and possible genetic syndromes. As an example, the American Cancer Society revealed that there were an expected 1,958,310 new cancer cases and 609,820 cancer-related deaths in 2023, in the United States. Projections for 2024 suggest a rise, with about 2,001,140 new cancer cases and 611,720 deaths projected, indicating a sustained increase in both cancer incidence and mortality rates. Thus, the accelerating prevalence of cancer is fueling the growth of the MSI-H and dMMR market.

Which Key Market Segments Comprise the MSI-H And dMMR Market and Drive Its Revenue Growth?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Which Areas Are Leading Regions in the MSI-H And dMMR Market Expansion Across the Globe?

North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theMSI-H And dMMR Market Direction?

Key players in the MSI-H and dMMR market are gearing toward the creation of novel treatments such as combination therapy, with the aim of augmenting treatment effectiveness and bolstering patient prognosis. Combination therapy for MSI-H and dMMR cancers works through the simultaneous application of two or more treatment methods, typically including immunotherapy components like checkpoint inhibitors or adding immunotherapy to chemotherapy, targeted therapy, or radiation. The intention behind this tactic is to boost response to treatment, overcome resistance, and aid in augmenting survival probabilities in patients with tumors demonstrating high microsatellite instability or deficient mismatch repair traits. For instance, Bristol-Myers Squibb Company, a pharmaceutical company based in the US, in April 2025, secured approval from the United States Food and Drug Administration (FDA) for the amalgamation of nivolumab (Opdivo) and ipilimumab (Yervoy), earmarked as an initial treatment strategy for metastatic colorectal cancer (mCRC) with features of either microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). This advanced the treatment opportunities for this obstinate category of cancer. The approval stands as a transformative event in the treatment landscape of MSI-H and dMMR cancers as it offers a new, potent treatment alternative which targets multiple routes to augment patient survival and response rates, thereby addressing the previously unfulfilled medical needs of this group of patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

How Is the MSI-H And dMMR Market Conceptually Defined?

MSI-H (microsatellite instability-high) and dMMR (deficient mismatch repair) refer to genetic abnormalities where the DNA repair system fails to correct replication errors, leading to high mutation rates. These markers are commonly found in certain cancers, such as colorectal and endometrial. Tumors with MSI-H and dMMR often respond well to immunotherapy due to their high immunogenicity.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24324

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the MSI-H And dMMR Market Size Changed, over the years?

The market size for MSI-H and dMMR has seen a rapid surge in the past few years. This market is projected to increase from $6.15 billion in 2024 to $7.59 billion in 2025, growing at a compound annual growth rate (CAGR) of 23.3%. Factors contributing to this demand during the historic period include a higher occurrence of colorectal and endometrial cancers, the expansion of genetic screening programs, greater clinical implementation of MSI testing, rising awareness regarding hereditary cancer syndromes, and the increasing acceptance of liquid biopsy.

How Much Will the MSI-H And dMMR Market Be Worth in 2029?

The market for MSI-H and dMMR is projected to expand significantly in the coming years, reaching a value of $17.40 billion in 2029 with a compound annual growth rate of 23.1%. This anticipated growth during the forecast period is due to factors such as the rising preference for tailored cancer treatments, the broadening scope of next-generation sequencing, increasing investment in cancer care, the proliferation of clinical trials for immune checkpoint inhibitors, and regulatory backing for companion diagnostics. The forecast period is also expected to see trends like the incorporation of artificial intelligence in diagnostic procedures, collaborations between pharmaceutical and diagnostic firms, the creation of multiplex biomarker panels, breakthroughs in immunotherapy, and a shift towards pan-cancer biomarker testing.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which is the Largest Company in the MSI-H And dMMR Market?

Major companies operating in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

What Are the Main Market Drivers in the MSI-H And dMMR Industry?

The acceleration in incidences of cancer is anticipated to boost the expansion of the MSI-H and dMMR market. Cancer is a collection of disorders distinguished by uncontrolled and unregulated growth and dissemination of abnormal body cells. This increase in incidences of cancer is mainly attributable to aging populations, since the chances of having cancer escalate considerably with age due to a combined effect of genetic mutations and prolonged exposure to threat factors over time. MSI-H and dMMR serve in cancer to spot tumors with high mutation frequencies because of defects in DNA rectification mechanisms. These biomarkers are beneficial in guiding immunotherapy decisions since such tumors are more probable to respond to immune checkpoint inhibitors, and they also offer insights into prognosis and possible genetic syndromes. For example, as per the American Cancer Society, a non-profit organization in the US, there were approximately 1,958,310 newly diagnosed cancer cases and 609,820 cancer-related fatalities predicted in the United States in 2023. These statistics are expected to surge in 2024, with around 2,001,140 new cancer instances and 611,720 deaths anticipated, indicating a continuous uprise in cancer occurrence and mortality. Consequently, the escalating prevalence of cancer propels the expansion of the MSI-H and dMMR market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

How Is the MSI-H And dMMR Market Segments Structured?

The MSI-H and dMMR market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Strategic Trends Are Transforming the MSI-H And dMMR Market?

Key players in the MSI-H and dMMR market are concentrating on creating cutting-edge treatments, such as combination therapy, to boost the effectiveness of treatments and enhance patient results. Combination therapy for MSI-H and dMMR cancers typically involves the use of several treatment methods, such as immunotherapy treatments like checkpoint inhibitors or combining immunotherapy with chemotherapy, targeted therapy, or radiation. This method is aimed at increasing treatment responsiveness, overcoming resistance, and boosting patient survival rates with tumors that show high microsatellite instability or deficient mismatch repair. For example, in April 2025, the American pharmaceutical company, Bristol-Myers Squibb Company, was granted approval by the United States Food and Drug Administration (FDA) to combine nivolumab (Opdivo) and ipilimumab (Yervoy) as an initial treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) characteristics, thus expanding treatment possibilities for this difficult cancer subtype. This approval is a notable milestone in the treatment of MSI-H and dMMR cancers, offering a novel, effective treatment option that targets several pathways to boost patient survival and response rates, meeting the unfulfilled medical needs of this patient group.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Global Regions Offer the Highest Growth in the MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

This Report Delivers Insight On:

1. How big is the msi-h and dmmr market, and how is it changing globally?

2. Who are the major companies in the msi-h and dmmr market, and how are they performing?

3. What are the key opportunities and risks in the msi-h and dmmr market right now?

4. Which products or customer segments are growing the most in the msi-h and dmmr market?

5. What factors are helping or slowing down the growth of the msi-h and dmmr market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model